CLINICAL RESPONSE TO ANTIPSYCHOTICS (ARIPIPRAZOLE, HALOPERIDOL, QUETIAPINE, ZUCLOPENTIXOL): CLINICAL EXOME PANEL (Sec. & CNVs) – 2 genes
Delivery time
3-4 weeks
Sample
Blood
The Clinical Response to Antipsychotics panel evaluates the main genetic variants that influence the metabolism, efficacy, and risk of adverse effects associated with the use of neuroleptics and atypical antipsychotics. The metabolism of these drugs depends primarily on the CYP2D6 and CYP3A4 enzymes, whose enzymatic activity exhibits wide interindividual variability. Slow metabolizers may present with elevated concentrations and an increased risk of sedation, extrapyramidal symptoms, or QT prolongation, while ultrarapid metabolizers may show therapeutic inefficacy. Genetic analysis allows for dose adjustment, selection of the most appropriate drug, and minimization of serious adverse reactions, optimizing safety and clinical response in personalized psychiatry. Key genes analyzed: CYP2D6 and CYP3A4.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€